Systematic review on randomized controlled trials for treatment of ventricular premature beat(VPB) by ShensongYangxin capsule
LI Yan-hong, ZHU Huai-jun
2009, 14(8):
915-923.
Asbtract
(
88 )
PDF (313KB)
(
170
)
References |
Related Articles |
Metrics
AIM: To evaluate the curative effect difference between ShensongYangxincapsule and Con-trol Group and the safety of them on ventricular prema-ture beat (VPB) .METHODS: Meta-analysis of 21-ShensongYangxin Capsule on the parameters commonly used treatment of VPB and other research literature on drug treatment of VPB, its effectiveness and safety for homogeneity test and the combined effect size estimate. RESULTS: Homogeneity test :Clinical effectiveness of the ECG :χ2=25.20, df=17, P=0 .090;Clinical ef-fectiveness:χ2=26.10, df=11, P=0.006;Clinical effectiveness of ventricular premature beats:χ2=7.13, df=5, P=0.211;Security 1 χ2=31.14, df=20, P=0.053, Security 2χ2=30.37, df=20, P=0.064.Combined effect size estimates: Effectiveness: Clinical effectiveness of the ECG:OR affiliate=1.04, 95%confidence interval of OR was [1.00, 1.09], Clinical effectiveness: OR affiliate=1.33, 95% confi-dence interval of OR was [1.19, 1.48] , Clinical ef-fectiveness of ventricular premature beats:OR affiliate=1.25, 95 % confidence interval of OR was [1 .13, 1.39] , Security 1 :OR affiliate=0.38, 95% confi-dence interval of OR was [0.28, 0.52] , Security 2: OR affiliate=0.39, 95% confidence interval of OR was [0.29, 0.52].CONCLUSION: The treatment of VPB ShensongYangxin capsule is better than the control group, Comparison of safety is also better control group and there is a significant difference .